Department of Analytical Chemistry, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic.
Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic.
Clin Biochem. 2019 Oct;72:39-51. doi: 10.1016/j.clinbiochem.2019.04.002. Epub 2019 Apr 4.
Due to the trend of prolonged lifespan leading to higher incidence of age-related diseases, the demand for reliable biomarkers of dementia rises. In this review, we present novel biomarkers of high potential, especially those found in blood, urine or saliva, which could lead to a more comfortable patient experience and better time- and cost-effectivity, compared to the currently used diagnostic methods. We focus on biomarkers that might allow for the detection of Alzheimer's disease before its clinical manifestations. Such biomarkers might be helpful for better understanding the etiology of the disease and identifying its risk factors. Moreover, it could be a base for developing new treatment or at least help to prolong the presymptomatic stage in patients suffering from Alzheimer's disease. As potential candidates, we present, for instance, neurofilament light in both cerebrospinal fluid and blood plasma or amyloid β in plasma. Above all, we provide an overview of different approaches to the diagnostics, analyzing patient's biofluids as a whole using molecular spectroscopy. Infrared and Raman spectroscopy and especially chiroptical methods provide information not only on the chemical composition, but also on molecular structure. Therefore, these techniques are promising for the diagnostics of Alzheimer's disease, as the accumulation of amyloid β in abnormal conformation is one of the hallmarks of this disease.
由于寿命延长导致与年龄相关的疾病发病率上升的趋势,对痴呆症可靠生物标志物的需求也在增加。在这篇综述中,我们提出了一些有很高潜力的新型生物标志物,特别是那些在血液、尿液或唾液中发现的生物标志物,与目前使用的诊断方法相比,这些生物标志物可能会带来更舒适的患者体验和更好的时间和成本效益。我们重点介绍了一些可能在阿尔茨海默病出现临床症状之前就能检测到的生物标志物。这些生物标志物可能有助于更好地了解疾病的病因,并确定其危险因素。此外,它还可以为开发新的治疗方法提供基础,或者至少有助于延长阿尔茨海默病患者的无症状期。作为潜在的候选者,我们提出了例如脑脊液和血浆中的神经丝轻链或血浆中的淀粉样β蛋白。最重要的是,我们提供了不同诊断方法的概述,通过分子光谱分析患者的生物流体整体。红外和拉曼光谱,特别是手性光学方法不仅提供了有关化学成分的信息,还提供了有关分子结构的信息。因此,这些技术对阿尔茨海默病的诊断具有很大的前景,因为异常构象中淀粉样β蛋白的积累是该疾病的特征之一。